Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$10.99M$10.99M−29.7% vs Q1 2021 Net Income-$5.10M-$5.10MN/M vs Q1 2021 EPS Diluted-$0.07-$0.07N/M vs Q1 2021 Operating Income-$7,457,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived-$23,032,000N/M Margins · derivedOperating margin-67.9%−35.5 pt vs Q1 2021
Net margin-46.4%−19.7 pt vs Q1 2021
ended Mar 31, 2022 · filed May 11, 2022 · 41 d after period end